Learn from science-founders and experienced industry professionals.
Receive one-on-one mentorship from experienced biotech entrepreneurs.
Craft a standout pitch and refine it with expert feedback.
Meet representatives from industry, venture funds and pharma.
Connect with ambitious peers, keep up with our thriving alumni network.
Earn ECTS credits and certification to showcase your expertise.
Kick off with a 2-day retreat and lay the foundation for your life science startup.
Learn to navigate drug development, map your market, and secure funding.
Test your idea, refine your pitching skills and present to a jury of industry experts.
Peter Nussbaumer has over 35 years experience in medicinal chemistry and drug discovery at Sandoz/Novartis. He is managing director of the Lead Discovery Center GmbH and Khanu Management GmbH, the general partner of KHAN Technology Transfer Fund I GmbH & Co KG, and its subsidiary wings4innovation GmbH. Peter is a member of several scientific advisory boards, advises private and public funding bodies and holds a PhD in organic chemistry from TU Wien.
Peter Nussbaumer has over 35 years experience in medicinal chemistry and drug discovery at Sandoz/Novartis. He is managing director of the Lead Discovery Center GmbH and Khanu Management GmbH, the general partner of KHAN Technology Transfer Fund I GmbH & Co KG, and its subsidiary wings4innovation GmbH. Peter is a member of several scientific advisory boards, advises private and public funding bodies and holds a PhD in organic chemistry from TU Wien.
Ulrich Granzer, PhD. is an independent consultant for drug development and regulatory affairs. He and his consultancy company are focusing on all aspects of drug development and regulatory affairs globally with a special emphasis on novel and orphan drugs. He has a track record of working on more than 300 new molecular entities in the US, Europe and other areas of the world.
Ulrich Granzer, PhD. is an independent consultant for drug development and regulatory affairs. He and his consultancy company are focusing on all aspects of drug development and regulatory affairs globally with a special emphasis on novel and orphan drugs. He has a track record of working on more than 300 new molecular entities in the US, Europe and other areas of the world.
Larissa Kahr has 20+ years’ experience in global pharma and finance, working on corporate and R&D strategies, new assets/technologies, risk management, market analysis, transformational technology projects, Due Diligence activities, CMC development, and set up a BD&L branch. Recently she expanded her expertise towards systemic organizational transformation and change management. Larissa holds a doctorate in biochemistry from the University of Vienna.
Larissa Kahr has 20+ years’ experience in global pharma and finance, working on corporate and R&D strategies, new assets/technologies, risk management, market analysis, transformational technology projects, Due Diligence activities, CMC development, and set up a BD&L branch. Recently she expanded her expertise towards systemic organizational transformation and change management. Larissa holds a doctorate in biochemistry from the University of Vienna.
Holger Ottleben, Ph.D. has over 20 years of experience in Pharma, Biotech, and Health Tech, gaining him profound knowledge of various therapeutic areas and the value chain. He served as General Manager in big pharma, top tier consulting and corporate. As co-founder of a biotech company, and board member of a VC backing start-up companies including clinical-stage biotech, micro-dispensing and telemedicine companies, he has significant start-up experience.
Holger Ottleben, Ph.D. has over 20 years of experience in Pharma, Biotech, and Health Tech, gaining him profound knowledge of various therapeutic areas and the value chain. He served as General Manager in big pharma, top tier consulting and corporate. As co-founder of a biotech company, and board member of a VC backing start-up companies including clinical-stage biotech, micro-dispensing and telemedicine companies, he has significant start-up experience.
Ghazaleh Gouya, a clinical regulatory expert and board-certified in internal medicine, cardiology, and clinical pharmacology, has 25+ years of experience in clinical research. At Gouya Insights, she leads a team of experts providing biotech, pharma, and medtech companies with tailored strategies for clinical development, guiding products efficiently from discovery through operational clinical trials to regulatory approval and market.
Ghazaleh Gouya, a clinical regulatory expert and board-certified in internal medicine, cardiology, and clinical pharmacology, has 25+ years of experience in clinical research. At Gouya Insights, she leads a team of experts providing biotech, pharma, and medtech companies with tailored strategies for clinical development, guiding products efficiently from discovery through operational clinical trials to regulatory approval and market.
Gregory Vladimer is co-founder and CEO of Graph Therapeutics, a next generation precision immunology techbio leveraging perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Greg was co-founder and CSO of Allcyte (acquired) and VP of Translational Research and Multimodal Discovery Lab at Exscientia. Greg also supports first-time founders as an advisor and angel investor.
Gregory Vladimer is co-founder and CEO of Graph Therapeutics, a next generation precision immunology techbio leveraging perturbation modeling from primary patient cell samples combined with multi-omics data to deliver transformative targeted therapies and biomarkers for immune-driven diseases. Greg was co-founder and CSO of Allcyte (acquired) and VP of Translational Research and Multimodal Discovery Lab at Exscientia. Greg also supports first-time founders as an advisor and angel investor.
Barbara Heitger is a widely recognized thought leader, advisor and author in organisational development and leadership. Her focus is on Corporate Development, Complex change processes/strategy implementation, International Leadership Development Programs, working with and coaching senior management teams.
Barbara Heitger is a widely recognized thought leader, advisor and author in organisational development and leadership. Her focus is on Corporate Development, Complex change processes/strategy implementation, International Leadership Development Programs, working with and coaching senior management teams.
Darryl McConnell works at Curie Bio building early stage Biotech companies. Previously Darryl was Senior Vice President and Research Site Head at Boehringer-Ingelheim’s Oncology Research Center in Vienna.
Darryl’s interests lie in drugging medicine´s most wanted drug targets with innovation and team science. Darryl studied chemistry and worked in Biotech in Australia and is author of over 75 peer reviewed publications and patents.
Darryl McConnell works at Curie Bio building early stage Biotech companies. Previously Darryl was Senior Vice President and Research Site Head at Boehringer-Ingelheim’s Oncology Research Center in Vienna.
Darryl’s interests lie in drugging medicine´s most wanted drug targets with innovation and team science. Darryl studied chemistry and worked in Biotech in Australia and is author of over 75 peer reviewed publications and patents.
Daniela Buchmayr has an engineering degree in biochemistry, biotechnology and genetic engineering and held various management positions in international companies in the biopharmaceutical sector for more than 15 years. As CEO and co-founder of Sarcura, a device platform to scale global manufacturing capacity focusing on CAR-T cell therapy, she is responsible for setting and leading the strategic direction of the company and organization.
Daniela Buchmayr has an engineering degree in biochemistry, biotechnology and genetic engineering and held various management positions in international companies in the biopharmaceutical sector for more than 15 years. As CEO and co-founder of Sarcura, a device platform to scale global manufacturing capacity focusing on CAR-T cell therapy, she is responsible for setting and leading the strategic direction of the company and organization.
Philipp Hainzl is the managing director of Vienna’s life sciences platform LISAvienna. He is responsible for the Vienna Business Agency’s Startup Labs at the Campus Vienna BioCenter. Furthermore, he helps shaping strategic decisions on the future development of this sector and is committed to providing infrastructure and laboratory space for life science start-ups.
Philipp Hainzl is the managing director of Vienna’s life sciences platform LISAvienna. He is responsible for the Vienna Business Agency’s Startup Labs at the Campus Vienna BioCenter. Furthermore, he helps shaping strategic decisions on the future development of this sector and is committed to providing infrastructure and laboratory space for life science start-ups.
Uros Tacar is a regulatory affairs and quality management expert with 30 years of experience in active medical devices.
He has gained extensive experience in the medical device industry as Head of Development and Head of Quality at a medical device manufacturer. More recently, he has been working as a consultant and is outsourced lead auditor at the notified body.
Uros Tacar is a regulatory affairs and quality management expert with 30 years of experience in active medical devices.
He has gained extensive experience in the medical device industry as Head of Development and Head of Quality at a medical device manufacturer. More recently, he has been working as a consultant and is outsourced lead auditor at the notified body.
Corinna Wilken completed her studies in Biochemistry at the University of Vienna and subsequently pursued her doctoral research at the Institute of Molecular Pathology (IMP).
Since 2007 she works for the Austrian Research Promotion Agency (FFG) leading the funding initiative Austrian Life Sciences Programme. At FFG, her duties encompass the evaluation of research and development projects undertaken by Austrian biotech companies.
Corinna Wilken completed her studies in Biochemistry at the University of Vienna and subsequently pursued her doctoral research at the Institute of Molecular Pathology (IMP).
Since 2007 she works for the Austrian Research Promotion Agency (FFG) leading the funding initiative Austrian Life Sciences Programme. At FFG, her duties encompass the evaluation of research and development projects undertaken by Austrian biotech companies.
Mark Caffrey earned a fellowship at the Translational Medical Device (TMD) Lab, gaining recognition as one of Ireland’s Leading Innovative Engineers. After founding his first neurotech venture-backed company, he shaped Syntropic Medical, where he now serves as CEO.
As serial neurotech entrepreneur, he brings extensive experience and deep expertise in medical device innovation, which has been instrumental in advancing Syntropic’s mission.
Mark Caffrey earned a fellowship at the Translational Medical Device (TMD) Lab, gaining recognition as one of Ireland’s Leading Innovative Engineers. After founding his first neurotech venture-backed company, he shaped Syntropic Medical, where he now serves as CEO.
As serial neurotech entrepreneur, he brings extensive experience and deep expertise in medical device innovation, which has been instrumental in advancing Syntropic’s mission.
Elisaweta Penewa Petrow has 15 years of experience in international Executive Search and Business Coaching & Training focusing on the Life Science Industry. She is founder of in-spectum and successfully developed and launched her own patented devices for drinking water analysis. Furthermore, she gained experience in Sales, Key Account Management, and Global Business Development in the Life Sciences Industry.
Elisaweta Penewa Petrow has 15 years of experience in international Executive Search and Business Coaching & Training focusing on the Life Science Industry. She is founder of in-spectum and successfully developed and launched her own patented devices for drinking water analysis. Furthermore, she gained experience in Sales, Key Account Management, and Global Business Development in the Life Sciences Industry.
Jack O’Keffee holds a Master’s in Biomedical Engineering and gained experience with industry leaders like Baxter and JnJ in medical device R&D. Through the Novo Nordisk Foundation Fellowship in Biomedical Design, he collaborated with top physicians on neurology challenges before joining Syntropic as CTO.
Jack brings hands-on expertise in needs-led innovation, product development, and design control, driving the company’s approach to impactful solutions.
Jack O’Keffee holds a Master’s in Biomedical Engineering and gained experience with industry leaders like Baxter and JnJ in medical device R&D. Through the Novo Nordisk Foundation Fellowship in Biomedical Design, he collaborated with top physicians on neurology challenges before joining Syntropic as CTO.
Jack brings hands-on expertise in needs-led innovation, product development, and design control, driving the company’s approach to impactful solutions.
Elvira Kainersdorfer is cluster manager at LISAvienna since October 2022. She has a background in technical chemistry specializing in biochemistry, biotechnology and food chemistry (Graz University of Technology). With previous roles at Roche Diagnostics and Olympus Austria, she later became Secretary General at Austria Wirtschaftsservice (2007). In 2011 she started working as investment manager in seed financing deep tech for life sciences.
Elvira Kainersdorfer is cluster manager at LISAvienna since October 2022. She has a background in technical chemistry specializing in biochemistry, biotechnology and food chemistry (Graz University of Technology). With previous roles at Roche Diagnostics and Olympus Austria, she later became Secretary General at Austria Wirtschaftsservice (2007). In 2011 she started working as investment manager in seed financing deep tech for life sciences.
Guido Gualdoni, co-founder and CEO of G.ST Antivirals, leads the development of a promising broad-spectrum antiviral nasal spray that recently concluded Phase 1 clinical trials. Holding both MD and PhD degrees in Immunology from the Medical University of Vienna, Guido has significantly contributed to viral infection research as a physician scientist at the General Hospital Vienna, focusing on metabolism-targeted therapies.
Guido Gualdoni, co-founder and CEO of G.ST Antivirals, leads the development of a promising broad-spectrum antiviral nasal spray that recently concluded Phase 1 clinical trials. Holding both MD and PhD degrees in Immunology from the Medical University of Vienna, Guido has significantly contributed to viral infection research as a physician scientist at the General Hospital Vienna, focusing on metabolism-targeted therapies.
Ingrid Kelly is a technology transfer professional and a Partner at xista science ventures, as well as a board member of biomedical startups Brainhero, Brightmind.AI and Hephaistos Pharma. She holds a PhD from the University of Cambridge (MRC Laboratory of Molecular Biology) and practiced as a European Patent Attorney in the Pharma industry.
Ingrid Kelly is a technology transfer professional and a Partner at xista science ventures, as well as a board member of biomedical startups Brainhero, Brightmind.AI and Hephaistos Pharma. She holds a PhD from the University of Cambridge (MRC Laboratory of Molecular Biology) and practiced as a European Patent Attorney in the Pharma industry.
Marco Masia is head of entrepreneurship at the University of Vienna, member of the investment advisory board of the Vienna technology incubator (INiTS), and serves as Academic Chair for innovation at the European University Initiative alliance Circle-U. For more than a decade, he has covered different roles at the intersection between research, innovation, and policy. He holds a PhD in Physics a MSc in Chemistry, and an executive MBA.
Marco Masia is head of entrepreneurship at the University of Vienna, member of the investment advisory board of the Vienna technology incubator (INiTS), and serves as Academic Chair for innovation at the European University Initiative alliance Circle-U. For more than a decade, he has covered different roles at the intersection between research, innovation, and policy. He holds a PhD in Physics a MSc in Chemistry, and an executive MBA.
Markus Pietzka supports entrepreneurs in conceiving, launching, and growing their business ideas into scalable businesses. Previously, he held roles in sales and logistics at international ICT firms. With a Ph.D. in chemistry from the University of Vienna, Markus brings interdisciplinary expertise to his endeavors.
Markus Pietzka supports entrepreneurs in conceiving, launching, and growing their business ideas into scalable businesses. Previously, he held roles in sales and logistics at international ICT firms. With a Ph.D. in chemistry from the University of Vienna, Markus brings interdisciplinary expertise to his endeavors.
Alexander Schwartz is a partner at xista, investing in and working with start-ups in life science, chemistry, and physics. He has more than 15 years consulting experience working for McKinsey and other companies. During this time he focussed on strategy, innovation, and business development in life science related industries. Alexander holds a PhD in chemistry, was a research fellow at ETH Zurich and a postdoctoral fellow at Harvard University.
Alexander Schwartz is a partner at xista, investing in and working with start-ups in life science, chemistry, and physics. He has more than 15 years consulting experience working for McKinsey and other companies. During this time he focussed on strategy, innovation, and business development in life science related industries. Alexander holds a PhD in chemistry, was a research fellow at ETH Zurich and a postdoctoral fellow at Harvard University.
Laura Fè holds a PhD in chemistry from the University of Leuven. She is an Italian and a European Patent Attorney, and head of the Murgitroyd Munich Office. Having worked in-house for global companies across a wide range of technologies, Laura is well-practised in understanding the dynamics and IP-related needs of a variety of clients and define strategic approaches that transform innovations into defendable assets that maintain their value.
Laura Fè holds a PhD in chemistry from the University of Leuven. She is an Italian and a European Patent Attorney, and head of the Murgitroyd Munich Office. Having worked in-house for global companies across a wide range of technologies, Laura is well-practised in understanding the dynamics and IP-related needs of a variety of clients and define strategic approaches that transform innovations into defendable assets that maintain their value.
Giuseppe Marzio, PhD, believes success begins with a great story—in business and in life. A scientist turned communication pro, he brings over 20 years of experience in health and life sciences. Giuseppe has guided CEOs of top startups, VCs, and corporations to secure major investments, close high-value deals, and drive success. An Amazon bestselling author and keynote speaker, he champions the power of stories to create a healthier planet.
Giuseppe Marzio, PhD, believes success begins with a great story—in business and in life. A scientist turned communication pro, he brings over 20 years of experience in health and life sciences. Giuseppe has guided CEOs of top startups, VCs, and corporations to secure major investments, close high-value deals, and drive success. An Amazon bestselling author and keynote speaker, he champions the power of stories to create a healthier planet.
Michael Lukesch is CEO and Founder of VALANX Biotech, a company using synthetic biology to address unmet needs in the production of protein bioconjugates like Antibody-Drug-Conjugates. He took VALANX’ technology from idea in 2017 all the way to commercial applications in 2023. He has a background in chemistry and biotechnology and a passion for enabling teams to take ideas from concept to reality.
Michael Lukesch is CEO and Founder of VALANX Biotech, a company using synthetic biology to address unmet needs in the production of protein bioconjugates like Antibody-Drug-Conjugates. He took VALANX’ technology from idea in 2017 all the way to commercial applications in 2023. He has a background in chemistry and biotechnology and a passion for enabling teams to take ideas from concept to reality.
Rudolf Dömötör is Director of WU Vienna Entrepreneurship Center and of the Entrepreneurship Center Network, a joint initiative of 31 Austrian universities promoting cross-disciplinary entrepreneurship. He is co-founder of Entrepreneurship Avenue, and co-author of the Austrian Startup Monitor, Austria’s largest startup study. Since summer 2022, he has been a member of the Startup Council of the Federal Ministry of Labor and Economic Affairs.
Rudolf Dömötör is Director of WU Vienna Entrepreneurship Center and of the Entrepreneurship Center Network, a joint initiative of 31 Austrian universities promoting cross-disciplinary entrepreneurship. He is co-founder of Entrepreneurship Avenue, and co-author of the Austrian Startup Monitor, Austria’s largest startup study. Since summer 2022, he has been a member of the Startup Council of the Federal Ministry of Labor and Economic Affairs.
Sanja Selak is a biotech and pharmaceutical executive, entrepreneur, scientist and innovator with 27 years of experience. She founded Origimm Biotechnology GmbH, which was acquired by Sanofi in 2021. At Origimm, Sanja designed and led R&D and business strategy from the idea to clinical phase, led multiple financing rounds, wrote patent applications and actively contributed to the innovation-focused and agile organisation of the company.
Sanja Selak is a biotech and pharmaceutical executive, entrepreneur, scientist and innovator with 27 years of experience. She founded Origimm Biotechnology GmbH, which was acquired by Sanofi in 2021. At Origimm, Sanja designed and led R&D and business strategy from the idea to clinical phase, led multiple financing rounds, wrote patent applications and actively contributed to the innovation-focused and agile organisation of the company.
Peter Kayatz, PhD, is CEO of Sola Diagnostics and Stams Diagnostics, developing cancer diagnostics and nanotechnology therapies. With extensive experience in drug development at AlcaSynn Pharmaceuticals, and as the owner of Waterbergh Management, Kayatz offers expertise in start-up consulting, business development, and financing. His contributions to life science startups are complemented by roles in various advisory boards and as a lecturer.
Peter Kayatz, PhD, is CEO of Sola Diagnostics and Stams Diagnostics, developing cancer diagnostics and nanotechnology therapies. With extensive experience in drug development at AlcaSynn Pharmaceuticals, and as the owner of Waterbergh Management, Kayatz offers expertise in start-up consulting, business development, and financing. His contributions to life science startups are complemented by roles in various advisory boards and as a lecturer.
Regina Weinmüllner has more than 20 years of experience working with various young companies, leading cooperations between several industrial partners and working as an international project manager in the pharmaceutical industry. As Investment Manager at Austria Wirtschaftsservice, she specializes in Deeptech Founders. Regina has a broad academic background in Life Sciences and holds a PhD in Biotechnology from the University of Natural Sciences in Vienna.
Regina Weinmüllner has more than 20 years of experience working with various young companies, leading cooperations between several industrial partners and working as an international project manager in the pharmaceutical industry. As Investment Manager at Austria Wirtschaftsservice, she specializes in Deeptech Founders. Regina has a broad academic background in Life Sciences and holds a PhD in Biotechnology from the University of Natural Sciences in Vienna.
Tibor Zechmeister is a startup founder, regulatory affairs manager and business leverager. His regulatory knowledge is based on three pillars of being an active part in multiple medical device startups, a consultant and an auditor for a European Notified Body. His entrepreneurial knowledge is based on over 11 years of being in the MedTech Startup ecosystem.
Tibor Zechmeister is a startup founder, regulatory affairs manager and business leverager. His regulatory knowledge is based on three pillars of being an active part in multiple medical device startups, a consultant and an auditor for a European Notified Body. His entrepreneurial knowledge is based on over 11 years of being in the MedTech Startup ecosystem.
Verena Winter has over 20 years experience as a tax-advisor specializing in the areas of start-ups as well as venture capital funds. Besides her position as director at BDO Austria GmbH, Verena is member of the advisory board of the Austria Wirtschaftsservice (aws) venture capital initiative. She completed her education in business studies at the University of British Columbia in Vancouver.
Verena Winter has over 20 years experience as a tax-advisor specializing in the areas of start-ups as well as venture capital funds. Besides her position as director at BDO Austria GmbH, Verena is member of the advisory board of the Austria Wirtschaftsservice (aws) venture capital initiative. She completed her education in business studies at the University of British Columbia in Vancouver.
Bernhard Hlatky is a lawyer at Wirtschaftskammer Wien, specializing in public law and commercial law. After completing his doctoral studies at the University of Vienna he worked as a Legal intern at the Higher Court of Justice in Vienna and for the law firm Fellner Wratzfeld und Partner. At Wirtschaftskammer Wien his job is to advice Viennese businesses in the fields of business and commercial law. © Marko’s photography
Bernhard Hlatky is a lawyer at Wirtschaftskammer Wien, specializing in public law and commercial law. After completing his doctoral studies at the University of Vienna he worked as a Legal intern at the Higher Court of Justice in Vienna and for the law firm Fellner Wratzfeld und Partner. At Wirtschaftskammer Wien his job is to advice Viennese businesses in the fields of business and commercial law. © Marko’s photography
Irmgard Nemec is an Attorney at Law at Herbst Kinsky Rechtsanwälte GmbH, specializing in intellectual-, industrial property- and unfair competition law. Irmgard advises start-ups and companies with a focus on biotech, life science and food&beverage. At Herbst Kinsky, she is a member of the Corporate/Start-Up/Venture Capital team advising clients in matters such as company foundations, financing measures and general corporate housekeeping.
Irmgard Nemec is an Attorney at Law at Herbst Kinsky Rechtsanwälte GmbH, specializing in intellectual-, industrial property- and unfair competition law. Irmgard advises start-ups and companies with a focus on biotech, life science and food&beverage. At Herbst Kinsky, she is a member of the Corporate/Start-Up/Venture Capital team advising clients in matters such as company foundations, financing measures and general corporate housekeeping.
Course Start: April 4th, 2025
1 Semester, 16 sessions, 2-3 hours
English
Some sessions in the Vienna area and some sessions online.
Limited spots,
Maximum 25 participants.
"I would recommend the course not only if you are in the process of creating a company, but even if you are thinking of doing so."
“Through xbio, I've gained the skills and insights necessary to move beyond my scientific bubble and embark on the journey of entrepreneurship.”
“Learning directly from other entrepreneurs is invaluable in preparing you for obstacles you might encounter on your own entrepreneurial journey.”
"A truly inspiring and insightful workshop series, offering invaluable guidance and mentorship for budding biotech entrepreneurs. Grateful for the wealth of knowledge shared!"
“Through the xbio course, I not only learned the vital steps in launching a biotech startup but also expanded my network significantly, fostering invaluable exchanges of ideas with fellow entrepreneurs in the field.”
"The experience in xbio was fundamental to familiarizing me with the Biotech Startup and making the transition from an academic role towards a more entrepreneurship adventure."
“Most in-depth material and best selection of experts I have had among several similar courses I had in the past.”
"The xbio course allowed me to take the initial step beyond the confines of my scientific sphere, significantly expanding my network and nurturing new ideas."
Individuals with life-science backgrounds, interested in founding a biomedical enterprise ideally have at least a rough idea about a technology and an unmet medical need they want to address. We also encourage potential co-founders with a business background to participate and use the program to find a venture to join or to deepen their understanding of the specifics of biomedical startups.
Our selection criteria take into account various factors, including:
The course is free of charge for members of supporting institutions:
ISTA, xista innovation, xista science ventures, ÖAW, TU Wien, Medical University Vienna, University of Vienna, VetMed, Wings4Innovation, KHAN, aws, INiTS, WU
For candidates beyond these institutions, there is a participation fee of EUR 1,500.-. Stipends for exceptional participants are available. Please apply to discuss details on your stipend eligibility.
Academic researchers of all levels, as well as early career professionals who are toying with the idea of founding or joining a biomedical company, are eligible.
The program demands a considerable commitment. Beyond attending sessions (13 sessions, average 4h, most in person) you will invest time in pre-reading, refining your idea, crafting a business plan outline, and preparing for the demo day presentation. In essence: Maintaining a certain level of enthusiasm and dedicating a few hours per week will be immensely beneficial.
While we strongly encourage attendance at all sessions, we understand that unforeseen circumstances may arise. You will be able to miss out on a maximum of 2 sessions – don’t worry, we will find a way to bring you up to speed on the missed content.